A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers

Drug and Alcohol Dependence

Volumn 74, Issue 2, 2004, Pages 205-209

  Mintzer, Miriam Z ^b   Correia, Christopher J ^a,b   Strain, Eric C ^b  

^a AUBURN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Cognitive performance; Neuropsychology; Opioid dependence; Pharmacotherapy

Indexed keywords

BUPRENORPHINE; NALOXONE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LONG TERM MEMORY; MALE; MEMORY; MENTAL PERFORMANCE; OPIATE ADDICTION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RECOGNITION; TABLET; TASK PERFORMANCE; TIME PERCEPTION; TREATMENT OUTCOME; WORKING MEMORY;

ADULT; BUPRENORPHINE; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY DISORDERS; NALOXONE; NARCOTIC ANTAGONISTS; NEUROPSYCHOLOGICAL TESTS; OPIOID-RELATED DISORDERS; PSYCHOMOTOR DISORDERS;

EID: 16544392790     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2003.12.008     Document Type: Article

References (33)

1. Appel P.W. Sustained attention in methadone patients. Int. J. Addict. 17:1982;1313-1327.
2. Appel P.W., Gordon N.B. Digit-symbol performance in methadone-treated ex-heroin addicts. Am. J. Psychiatry. 133:1976;1337-1340.
3. Darke S., Sims J., McDonald S., Wickes W. Cognitive impairment among methadone maintenance patients. Addiction. 95:2000;687-695.
4. Fudala P.J., Bridge T.P. Guest Editors, Supplement: Buprenorphine and buprenorphine/naloxone: A guide for clinicians. Drug Alcohol Depend. 70:2003;S1-S104.
5. Fudala P.J., Yu E., Macfadden W., Boardman C., Chiang C.N. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 50:1998;1-8.
6. Goodman L.A., Kruskal W.H. Measures of association for cross-classifications. J. Am. Stat. Assoc. 49:1954;732-764.
7. Gordon N.B. Reaction-times of methadone treated ex-heroin addicts. Psychopharmacologia. 16:1970;337-344.
8. Gritz E.R., Shiffman S.M., Jarvik M.E., Haber J., Dymond A.M., Coger R., Charuvastra V., Schlesinger J. Physiological and psychological effects of methadone in man. Arch. Gen. Psychiatry. 32:1975;237-242.
9. Halstead, W.C., 1947. Brain and Intelligence. University of Chicago Press, Chicago.
10. Jonides J., Schumacher E.H., Smith E.E., Lauber E.J., Awh E., Minoshima S., Koeppe R.A. Verbal working memory load affects regional brain activation as measured by PET. J. Cogn. Neurosci. 9:1997;462-475.
11. Lombardo W.K., Lombardo B., Goldstein A. Cognitive functioning under moderate and low dosage methadone maintenance. Int. J. Addict. 11:1976;389-401.
12. McLeod D.R., Griffiths R.R., Bigelow G.E., Yingling J. An automated version of the digit symbol substitution test (DSST). Behav. Res. Methods Instrum. 14:1982;463-466.
13. Mendelson J., Jones R.T., Brown W.S., Batki S.L. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol. Psychiatr. 41:1997;1095-1101.
14. Mintzer M.Z., Frey J.M., Yingling J.E., Griffiths R.R. Triazolam and zolpidem: A comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav. Pharmacol. 8:1997;561-574.
15. Mintzer M.Z., Stitzer M.L. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend. 67:2002;41-51.
16. Moskowitz, H., Robinson, C.D., 1985. Methadone maintenance treatment and tracking performance. In: Kaye, S., Meier, G.W. (Eds.), Alcohol, Drugs and Traffic Safety, U.S. Department of Transportation, pp. 995-1004.
17. Pickworth W.B., Johnson R.E., Holicky B.A., Cone E.J. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin. Pharmacol. Ther. 53:1993;570-576.
18. Preston K.L., Bigelow G.E., Liebson I.A. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology. 94:1988;484-490.
19. Preston K.L., Bigelow G.E., Liebson I.A. Antagonist effects of nalbuphine in opioid-dependent human volunteers. J. Pharmacol. Exp. Ther. 248:1989;929-937.
20. Preston K.L., Bigelow G.E., Liebson I.A. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend. 25:1990;27-34.
21. Preston K.L., Liebson I.A., Bigelow G.E. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination. J. Pharmacol. Exp. Ther. 261:1992;62-71.
22. Reitan R.M. Investigation of the validity of Halstead's measure of biological intelligence. Arch. Neurol. Psychiatry. 73:1955;28-35.
23. Robinson, C.D., Moskowitz, H., 1985. Methadone maintenance treatment and aspects of skilled performance. In: Kaye, S., Meier, G.W. (Eds.), Alcohol, Drugs and Traffic Safety, U.S. Department of Transportation, pp. 1145-1157.
24. Rothenberg S., Schottenfeld S., Meyer R.E., Krauss B., Gross K. Performance differences between addicts and non-addicts. Psychopharmacology. 52:1977;299-306.
25. Soyka M., Horak M., Dittert S., Kagerer S. Less driving impairment on buprenorphine than methadone in drug-dependent patients? J. Neuropsychiatry Clin. Neurosci. 13:2001;527-528.
26. Specka M., Finkbeiner T., Lodemann E., Leifert K., Kluwig J., Gastpar M. Cognitive-motor performance of methadone-maintained patients. Eur. Addict. Res. 6:2000;8-19.
27. Stoller K.B., Bigelow G.E., Walsh S.L., Strain E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology. 154:2001;230-242.
28. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J. Pharmacol. Exp. Ther. 261:1992;985-993.
29. Strain E.C., Stoller K., Walsh S.L., Bigelow G.E. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology. 148:2000;374-383.
30. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin. Pharmacol. Ther. 55:1994;569-580.
31. Walsh S.L., Preston K.L., Bigelow G.E., Stitzer M.L. Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274:1995;361-372.
32. Wechsler, D., 1955. A Manual for the Wechsler Adult Intelligence Scale. Psychological Corporation, New York.
33. Zacny J.P. A review of the effects of opioids on psychomotor and cognitive functioning in humans. Exp. Clin. Psychopharmacol. 3:1995;432-466.